Profile data is unavailable for this security.
About the company
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
- Revenue in USD (TTM)3.18bn
- Net income in USD-3.36bn
- Incorporated2016
- Employees5.80k
- LocationModerna Inc325 BINNEY STREETCambridge 02142United StatesUSA
- Phone+1 (617) 714-6500
- Fax+1 (617) 583-1998
- Websitehttps://www.modernatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals PLC | 4.06bn | 482.20m | 6.95bn | 2.80k | 15.31 | 1.70 | 6.07 | 1.71 | 7.50 | 7.50 | 63.69 | 67.75 | 0.3556 | 0.8501 | 5.98 | 1,451,717.00 | 4.23 | 1.36 | 4.81 | 1.50 | 88.81 | 88.18 | 11.88 | 3.98 | 2.97 | 2.56 | 0.5625 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| Halozyme Therapeutics, Inc. | 1.08bn | 485.36m | 7.12bn | 350.00 | 15.34 | 14.76 | 12.56 | 6.57 | 3.77 | 3.77 | 8.42 | 3.92 | 0.537 | 1.08 | 4.33 | 3,098,017.00 | 24.04 | 22.20 | 25.84 | 25.70 | 83.45 | 80.85 | 44.76 | 45.39 | 7.30 | -- | 0.7576 | 0.00 | 22.44 | 38.95 | 57.71 | -- | 21.50 | -- |
| Elanco Animal Health Inc | 4.43bn | 373.00m | 7.43bn | 9.00k | 19.99 | 1.17 | 7.21 | 1.68 | 0.7483 | 0.7483 | 8.92 | 12.80 | 0.3284 | 1.24 | 4.52 | 491,888.90 | 2.77 | -2.71 | 3.05 | -3.02 | 54.89 | 54.72 | 8.43 | -9.52 | 1.46 | 1.14 | 0.4089 | -- | 0.4981 | 7.65 | 127.46 | 37.85 | -3.99 | -- |
| Corcept Therapeutics Inc | 685.45m | 133.99m | 7.75bn | 500.00 | 62.82 | 11.34 | 57.14 | 11.31 | 1.16 | 1.16 | 5.91 | 6.45 | 0.9125 | 0.9973 | 11.12 | 1,370,892.00 | 17.84 | 20.07 | 21.23 | 23.01 | 98.43 | 98.53 | 19.55 | 24.89 | 2.96 | -- | 0.00 | 0.00 | 39.94 | 17.11 | 33.04 | 8.44 | 14.83 | -- |
| Roivant Sciences Ltd | 29.05m | -545.01m | 7.92bn | 750.00 | -- | 1.73 | -- | 272.60 | -0.7559 | -0.2408 | 0.04 | 6.74 | 0.0046 | -- | -- | 38,737.33 | -11.53 | 5.89 | -12.96 | 6.98 | 96.86 | 90.39 | -2,511.84 | 639.97 | -- | -- | 0.00 | 0.00 | -11.19 | -15.56 | -111.69 | -- | -1.32 | -- |
| BridgeBio Pharma Inc | 127.42m | -667.97m | 8.88bn | 725.00 | -- | -- | -- | 69.65 | -3.53 | -3.53 | 0.6744 | -8.68 | 0.1472 | -- | -- | 175,744.80 | -78.20 | -75.74 | -95.66 | -94.24 | 95.35 | 96.67 | -531.17 | -716.92 | 4.54 | -4.69 | 3.32 | -- | 2,285.27 | 40.48 | 16.70 | -- | 11.63 | -- |
| Viatris Inc | 14.33bn | -3.79bn | 10.88bn | 32.00k | -- | 0.7024 | -- | 0.7592 | -3.18 | -3.18 | 12.00 | 13.20 | 0.334 | 2.15 | 5.33 | 447,818.80 | -8.83 | -0.1756 | -10.48 | -0.2096 | 40.69 | 40.66 | -26.45 | -0.5768 | 0.9661 | 2.89 | 0.4753 | -- | -4.46 | 5.09 | -1,259.42 | -- | -3.10 | -- |
| Biomarin Pharmaceutical Inc | 2.95bn | 523.88m | 11.19bn | 3.04k | 21.66 | 1.93 | 18.20 | 3.79 | 2.69 | 2.69 | 14.92 | 30.21 | 0.4209 | 0.5028 | 4.29 | 970,469.40 | 7.47 | 2.18 | 8.52 | 2.46 | 79.44 | 76.43 | 17.76 | 6.07 | 3.49 | -- | 0.0932 | 0.00 | 17.97 | 10.86 | 154.62 | -- | -9.83 | -- |
| Moderna Inc | 3.18bn | -3.36bn | 12.45bn | 5.80k | -- | 1.24 | -- | 3.92 | -8.71 | -8.71 | 8.17 | 26.01 | 0.2159 | 4.70 | 29.55 | 547,758.60 | -22.81 | 13.72 | -26.38 | 18.76 | 68.68 | 76.34 | -105.67 | 23.74 | 4.14 | -- | 0.0062 | 0.00 | -52.75 | 121.86 | 24.46 | -- | 101.61 | -- |
| Neurocrine Biosciences Inc | 2.41bn | 305.80m | 13.27bn | 1.80k | 45.46 | 5.24 | 39.70 | 5.50 | 2.95 | 2.95 | 23.34 | 25.61 | 0.6739 | 0.7414 | 4.99 | 1,340,333.00 | 8.54 | 10.41 | 10.32 | 12.71 | 98.52 | 98.47 | 12.68 | 15.71 | 3.02 | 17.53 | 0.00 | -- | 24.81 | 24.48 | 36.68 | 55.94 | 20.97 | -- |
| Incyte Corp | 4.41bn | 21.27m | 13.34bn | 2.62k | 249.05 | 3.64 | 120.30 | 3.02 | 0.2768 | 0.2768 | 21.55 | 18.93 | 0.685 | 4.71 | 5.63 | 1,686,368.00 | 0.3302 | 6.35 | 0.4355 | 7.89 | 93.19 | 94.43 | 0.482 | 9.56 | 2.00 | -- | 0.01 | 0.00 | 14.76 | 14.46 | -94.54 | -40.76 | 2.02 | -- |
| United Therapeutics Corp | 2.99bn | 1.21bn | 13.41bn | 1.31k | 11.85 | 1.97 | 10.41 | 4.48 | 25.08 | 25.08 | 62.05 | 151.02 | 0.4206 | 2.31 | 9.52 | 2,294,330.00 | 17.01 | 13.61 | 19.13 | 14.84 | 89.00 | 90.79 | 40.44 | 37.81 | 5.23 | -- | 0.0285 | 0.00 | 23.63 | 14.71 | 21.35 | -- | 24.11 | -- |
Data as of Jul 18 2025. Currency figures normalised to Moderna Inc's reporting currency: US Dollar USD
38.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 38.87m | 10.07% |
| Baillie Gifford & Co.as of 31 Mar 2025 | 24.95m | 6.47% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2025 | 20.30m | 5.26% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 17.87m | 4.63% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 17.78m | 4.61% |
| Geode Capital Management LLCas of 31 Mar 2025 | 7.46m | 1.93% |
| Th�l�me Partners LLPas of 31 Mar 2025 | 7.24m | 1.88% |
| D. E. Shaw & Co. LPas of 31 Mar 2025 | 5.64m | 1.46% |
| Invesco Capital Management LLCas of 31 Mar 2025 | 5.39m | 1.40% |
| Two Sigma Investments LPas of 31 Mar 2025 | 4.45m | 1.15% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
